hotspot -WSS

hotspot

author：entertainment 2025-09-30 18:43:09 - browse：2

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Mifepristone protocols being wielded by pill's opponents in Supreme Court case

hotspot

WSS

Chemotherapy before breast cancer surgery might fuel metastasis

Brain technologies pose threats that are all too real, experts warn

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Redefining sustainability for the pharmaceutical industry

Medicare isn't yet testing food as medicine

STAT Madness 2024: Meet the contenders

entertainment

hotspot

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Primary care doctor shortage won't be solved by free med school tuition

Drug repurposing or repositioning? The language matters

PBM executives asked to testify by House panel

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Beam, Prozac, "TechBio" and more

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Chemotherapy before breast cancer surgery might fuel metastasis

In age of alternative facts, a scholarly course on calling out crap

Childhood vaccination ad campaign launches in the U.K.

hotspot

Deliver public health messages at the right time

Warren pushes Witty on UnitedHealth's control over physicians

CDC panel: People 65 and older should get a Covid spring booster shot

As health system earnings go up, health insurance stocks go down

Ohio train derailment: Experts on toxic chemical risks

Brain MRIs reveal impact of 'toxic stress' on Black children

focus

hotspot

focus

hotspot